Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
India has taken the lead in recognising NAFLD as a major non-communicable disease
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
Subscribe To Our Newsletter & Stay Updated
